2019, Number 2
<< Back Next >>
CorSalud 2019; 11 (2)
Arrhythmias caused by ondansetron: Case report
Chala TJM, Jiménez FL, Armada EZ, Brito FY, Zayas GM, García AM
Language: Spanish
References: 12
Page: 171-174
PDF size: 449.55 Kb.
ABSTRACT
The ondansetron is used to prevent nausea and vomiting caused by chemotherapy, radiotherapy and surgery, belonging to the serotonin 5-HT3 receptor antagonists, a natural substance that can cause nausea and vomiting, and it blocks its
action. The ondansetron is packaged in the form of rapid disintegration tablets, as
a solution to be taken orally and in ampules, for parenteral use. The case of a 67-
year-old female patient is presented, with a diagnosis of breast carcinoma, who
underwent radical mastectomy with axillary dissection was performed, and who
received chemotherapy with adriamycin, cyclophosphamide and paclitaxel; as
well as ondansetron to treat nausea and vomiting. The patient presented a wide
QRS complex tachycardia after taking the drug.
REFERENCES
Morón Rodríguez FJ, Levi Rodríguez M. Farmacología General. La Habana: Ciencias Médicas; 2002. [ Links ]
Flórez J, Armijo JA, Mediavilla A. Farmacología humana. 6ª ed. Barcelona: Elsevier España; 2014. [ Links ]
Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw-Hill Education; 2018. [ Links ]
Brião FF, Horta ML, Horta BL, de Barros GA, Behrensdorf AP, Severo I, et al. Comparison of droperidol and ondansetron prophylactic effect on subarachnoid morphine-induced pruritus. Braz J Anesthesiol. 2015 Jul-Aug;65(4):244-8. [ Links ]
Ministerio de Salud Pública. Formulario Nacional de Medicamentos. La Habana: Editorial Ciencias Médicas; 2014. [ Links ]
Tricco AC, Soobiah C, Antony J, Hemmelgarn B, Moher D, Hutton B, et al. Safety of serotonin (5-HT3) receptor antagonists in patients undergoing surgery and chemotherapy: protocol for a systematic review and network meta-analysis. Syst Rev [Internet]. 2013 [citado 31 Mar 2019];2:46. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3702491/pdf/2046-4053-2-46.pdf [ Links ]
McKechnie K, Froese A. Ventricular tachycardia after ondansetron administration in a child with undiagnosed long QT syndrome. Can J Anesth. 2010;57(5):453-7. [ Links ]
Buyukavci M, Olgun H, Ceviz N. The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia. Am J Clin Oncol. 2005;28(2):201-4. [ Links ]
Freedman SB, Hall M, Shah SS, Kharbanda AB, Aronson PL, Florin TA, et al. Impact of increasing ondansetron use on clinical outcomes in children with gastroenteritis. JAMA Pediatr. 2014;168(4):321-9. [ Links ]
Brenner SM, Boucher J. Fatal Cardiac Arrest in 2 Children: Possible Role of Ondansetron. Pediatr Emerg Care. 2016;32(11):779-84. [ Links ]
Faria C, Li X, Nagl N, McBride A. Outcomes Associated with 5-HT3-RA Therapy Selection in Patients with Chemotherapy-Induced Nausea and Vomiting: A Retrospective Claims Analysis. Am Health Drug Benefits. 2014;7(1):50-8. [ Links ]
Schwartzberg L, Barbour SY, Morrow GR, Ballinari G, Thorn MD, Cox D. Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Support Care Cancer. 2014;22(2):469-77. [ Links ]
Full text